Associated tags: Arginine, Therapy, European Medicines Agency, Homocystinuria, DSM-IV codes, Pharmaceutical industry, Patient, Engineering, Enzyme, Arginase
Locations: LONDON, TEXAS, NEW YORK, EUROPE, MASSACHUSETTS, UNITED KINGDOM, UK
Retrieved on:
Monday, November 27, 2023
JD,
Pfizer,
Acquisition,
Engineering,
CFO,
Patient,
FIH,
Novartis,
Growth,
Doctor of Philosophy,
Risankizumab,
DevOps,
Drug discovery,
SYRE,
Genentech,
Spark Therapeutics,
Corporation,
Johnson & Johnson,
Therapy,
TL1A,
SVP,
Intellectual property,
Ustekinumab,
Inflammatory bowel disease,
Disease,
Medicine,
FDA,
Crohn's disease,
IBD,
MD,
Mirati Therapeutics,
CMC,
Pharmaceutical industry,
Management,
Vaccine,
Michael Spyres,
Burrill Bernard Crohn WALTHAM, Mass., Nov. 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol "SYRE". The name change follows the acquisition of privately held Spyre Therapeutics, Inc. by the Company in June of 2023. Named to reflect the Company's ambition to achieve new heights in efficacy and convenience of Inflammatory Bowel Disease (IBD) therapies, Spyre aims to create a next-generation of IBD products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision patient selection approaches to enhance efficacy for patients.
Key Points:
- Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol "SYRE".
- The name change follows the acquisition of privately held Spyre Therapeutics, Inc. by the Company in June of 2023.
- The Company also announced today the appointment of Cameron Turtle, DPhil as Chief Executive Officer (CEO) and member of the Board of Directors.
- SPY001 is currently progressing through IND-enabling studies and is expected to enter first-in-human ("FIH") studies in the first half of 2024.
Retrieved on:
Tuesday, October 31, 2023
WALTHAM, Mass., Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences:
Key Points:
- WALTHAM, Mass., Oct. 30, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences:
Guggenheim 5th Annual Inflammation & Immunology Conference, New York, New York – November 7th, 2023
Stifel 2023 Annual Healthcare Conference, New York, New York – November 14th, 2023
Jefferies 2023 London Healthcare Conference, London, UK – November 15-16th, 2023
To access the webcast of Aeglea's presentations, please visit the "Events & Presentations" page within the Investors section of the Aeglea website at ir.aeglea.com.
Retrieved on:
Tuesday, September 5, 2023
Treasury,
Amgen,
Common stock,
Employment,
University,
Eteplirsen,
Therapy,
General counsel,
International,
Kirin-Amgen Inc v Hoechst Marion Roussel Ltd,
IBD,
Sarepta,
Cornell Law School,
Arthur Andersen,
Record,
Corporate law,
MBA,
Dartmouth College,
Inflammatory bowel disease,
Sarepta Therapeutics,
Rope,
Comparative law,
Acquisition,
Doctor of Philosophy,
Patient,
Corporation,
CPA,
Sanofi,
Security (finance),
TL1A,
BA,
Pharmaceutical industry,
Management WALTHAM, Mass., Sept. 5, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary. Both will report to Cameron Turtle, Chief Operating Officer of Aeglea, and join the Company's leadership team. Aeglea also announced that Jonathan Alspaugh, Aeglea's current President and Chief Financial Officer, is expected to transition into a strategic advisory consulting role through December 31, 2023.
Key Points:
- Both will report to Cameron Turtle, Chief Operating Officer of Aeglea, and join the Company's leadership team.
- "Scott and Heidy both bring extraordinary expertise and leadership skills through their proven track records at public biopharma companies with both investigational and commercialized products," said Cameron Turtle, DPhil.
- On behalf of the management team and Board of Directors, I would also like to thank Jonathan for his steadfast commitment to the company."
- Mr. Burrows is a veteran of the biopharma industry with more than two decades of diverse experience and a proven track-record in biopharmaceutical finance leadership roles spanning multiple public companies.
DSM-IV codes,
CVR,
Therapy,
Contingent value rights,
IBD,
Sale,
Inflammatory bowel disease,
Acquisition,
FDA,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Food,
Pharmaceutical industry WALTHAM, Mass., July 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with best-in-class potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency ("ARG1-D"), to Immedica Pharma AB ("Immedica") for $15 million in upfront cash proceeds and up to $100 million in contingent milestone payments. The sale of pegzilarginase to Immedica supersedes the previous license agreement between Aeglea and Immedica.
Key Points:
- The sale of pegzilarginase to Immedica supersedes the previous license agreement between Aeglea and Immedica.
- "We are thrilled that Immedica will be continuing our efforts with pegzilarginase and consolidating development of the potential therapy for the treatment of ARG1-D," said Jonathan Alspaugh, President and Chief Financial Officer of Aeglea.
- "Immedica has made substantial progress in working towards a European market approval.
- The milestone payments are contingent on formal reimbursement decisions by national authorities in key European markets and pegzilarginase approval by the U.S. Food and Drug Administration ("FDA"), among other events.
Paragon,
LLP,
Therapy,
Doctor of Philosophy,
Investment,
Diarrhea,
IBD,
Biotechnology,
Weight loss,
TL1A,
Research,
Abdominal pain,
Sale,
Ulcerative colitis,
Inflammatory bowel disease,
Crohn's disease,
Richard Driehaus,
Acquisition,
Patient,
Capital,
SVP,
Safety,
Fatigue,
Corporate development,
Vaccine,
Pharmaceutical industry,
Management,
Citadel,
Michael Spyres AUSTIN, Texas and WALTHAM, Mass., June 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a privately held biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Concurrent with the acquisition of Spyre, Aeglea entered into a definitive agreement for the sale of Series A non-voting convertible preferred stock (the "Series A preferred stock") in a private placement to a group of institutional accredited investors led by Fairmount Funds Management LLC ("Fairmount Funds"), with participation from Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Commodore Capital, Deep Track Capital, Perceptive Advisors, RTW Investments, Cormorant Asset Management, Driehaus Capital Management, Ecor1 Capital, RA Capital Management, Surveyor Capital (a Citadel company), and Wellington Management Company LLP, as well as additional undisclosed institutional investors. The private placement is expected to result in gross proceeds to Aeglea of approximately $210 million before deducting placement agent and other offering expenses. The proceeds from the private placement are intended to be used to advance Spyre's portfolio of potentially best-in-class IBD products through multiple data milestones and are expected to fund operations into 2026.
Key Points:
- Spyre is the second spinout of Paragon Therapeutics.
- Spyre was founded to transform the treatment of IBD by pursuing potentially best-in-class long-acting antibodies, rational therapeutic combinations, and precision immunology approaches.
- "The concurrent launch of Spyre and acquisition by Aeglea will provide immediate access to the public capital markets and the opportunity to accelerate research and development efforts for our broad pipeline of biologics," said Cameron Turtle, DPhil, newly appointed Chief Operating Officer of Aeglea.
- "Our management and our Board of Directors thoroughly explored numerous strategic alternatives and believe this acquisition of Spyre provides a phenomenal outcome for our stockholders," said Jonathan D. Alspaugh, President and Chief Financial Officer, Aeglea.
Linda,
Patient,
MBA,
License,
DSM-IV codes,
FDA,
European Medicines Agency,
Clinical trial,
Marketing,
OLE,
Arginase,
Homocystinuria,
Safety,
MD,
Research,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
BLA,
Therapy,
LTE,
EMA,
Food,
Investigational New Drug,
Pharmaceutical industry,
Management,
Cryptocurrency,
Cystinuria AUSTIN, Texas, March 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates.
Key Points:
- Research and development expenses totaled $14.3 million for the fourth quarter of 2022 and $16.8 million for the fourth quarter of 2021.
- General and administrative expenses totaled $5.0 million for the fourth quarter of 2022 and $7.3 million for the fourth quarter of 2021.
- Net loss totaled $18.8 million and $20.4 million for the fourth quarter of 2022 and 2021, respectively, which includes non-cash stock compensation expense of $1.4 million and $2.1 million for the fourth quarter of 2022 and 2021, respectively.
- As of December 31, 2022, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $57.3 million.
Fordham University,
Samsung Biologics,
Biotechnology,
Knowledge,
Journal of Global Drug Policy and Practice,
Workforce,
Homocystinuria,
United,
Patient,
University,
M.B.A,
Therapy,
University of Texas at Austin,
Cystinuria,
Vetter Pharma,
Management,
Psychology,
Genentech,
Biology AUSTIN, Texas, Jan. 6, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced an update to its corporate structure. These changes are in addition to the restructuring process that was initiated in August 2022 and are intended to further streamline the organization, create operational efficiencies to support near- and long-term objectives and maximize the value of the company's two clinical programs.
Key Points:
- AUSTIN, Texas, Jan. 6, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced an update to its corporate structure.
- As part of these additional changes, the workforce of the company has been further reduced by approximately 15%.
- Aeglea is also halting the preclinical work on the Cystinuria and other unnamed pipeline programs.
- Ms. Caudill joined Aeglea in 2019 and has served as a valued leader of the company's manufacturing, technical operations and pegtarviliase program teams.
Retrieved on:
Wednesday, November 30, 2022
COVID-19,
Doctor of Philosophy,
JD,
European Medicines Agency,
Intellectual disability,
MAA,
Piper Sandler Companies,
Frank Lenti,
MS,
Osteoporosis,
Engineering,
Metabolic disorder,
Conference,
Compte rendu,
Multimedia,
Therapy,
Physician,
Enzyme,
MBA,
Patient,
Massachusetts Institute of Technology,
Genzyme,
Disease,
CBS,
Cornell University,
Marfanoid,
Security (finance),
Proteostasis,
Death,
Risk,
Arginine,
Chemical engineering,
Pharmaceutical industry,
Management,
Homocystinuria Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and chief executive officer of Immunitas Therapeutics.
Key Points:
- Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and chief executive officer of Immunitas Therapeutics.
- I look forward to working closely with Jeff and welcome him to the Aeglea team."
- Mr. Goldberg served as president and chief executive officer at Immunitas from 2019-2021.
- Jim Kastenmayer, JD, PhD, will step down as interim chief executive officer and retain his position as Aeglea's general counsel.
Retrieved on:
Tuesday, November 15, 2022
Linda,
SEC,
Compte rendu,
M.B.A,
Haemophilia,
U.S. Securities and Exchange Commission,
Security (finance),
MAA,
Investigational New Drug,
European Medicines Agency,
Enzyme,
Southern Illinois University School of Medicine,
Therapy,
Biology,
Forward-looking statement,
Risk,
NDA,
Leadership,
Homocystinuria,
New Drug Application,
Medicine,
Industry,
Adverum Biotechnologies,
Multimedia,
Patient,
Indiana Wesleyan University,
COVID-19,
NASDAQ,
Ophthalmology,
University School,
Private Securities Litigation Reform Act,
Review,
IND,
Drug development,
Engineering,
Arginine,
Pharmaceutical industry,
Management,
Catalysis,
Southern Illinois University AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.
Key Points:
- AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.
- D., J.D., interim chief executive officer and general counsel of Aeglea.
- I am excited to continue working closely with Linda as a valued member of our executive leadership team."
- Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options.
Retrieved on:
Wednesday, October 19, 2022
Boston Children's Hospital,
European Medicines Agency,
Therapy,
CBS,
Hospital,
Review,
Lists of diseases,
NASDAQ,
Patient,
Pediatrics,
Enzyme,
Multimedia,
Harvard Medical School,
Company,
Arginine,
MD,
Q&A,
KOL,
Engineering,
Pharmaceutical industry,
Online shopping,
Homocystinuria AUSTIN, Texas, Oct. 19, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it will host a key opinion leader (KOL) webinar on Classical Homocystinuria, and Aeglea's potential treatment and lead clinical asset pegtarviliase on Thursday, October 27, 2022 at 10:00 AM Eastern Time.
Key Points:
- The webinar will feature KOL Harvey Levy, MD, who will discuss the unmet medical need and current treatment landscape for patients suffering from Classical Homocystinuria, also known as cystathionine beta synthase (CBS) deficiency.
- The Aeglea management team will provide an overview of their potential treatment solution, pegtarviliase, a human enzyme therapy which is currently in Phase 1/2 clinical development.
- Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options.
- Aeglea is investigating pegtarviliase in an ongoing Phase 1/2 clinical trial for the treatment of Homocystinuria.
